Terms: = Kidney tumors AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
848 results:
1. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
2. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with pd-1/PD-L1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract] [Full Text] [Related]
3. A three-gene expression score for predicting clinical benefit to anti-pd-1 blockade in advanced renal cell carcinoma.
Betancor YZ; Ferreiro-Pantín M; Anido-Herranz U; Fuentes-Losada M; León-Mateos L; García-Acuña SM; Vaamonde-Rodríguez V; García-Pinel B; Cebey-López V; Villaverde-Viaño R; Lombardía-Rodríguez H; Kotrulev M; Fernández-Díaz N; Gomez-Tourino I; Fernández-Baltar C; García-González J; Tubio JMC; López-López R; Ruiz-Bañobre J
Front Immunol; 2024; 15():1374728. PubMed ID: 38660294
[TBL] [Abstract] [Full Text] [Related]
4. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
Wolf MM; Madden MZ; Arner EN; Bader JE; Ye X; Vlach L; Tigue ML; Landis MD; Jonker PB; Hatem Z; Steiner KK; Gaines DK; Reinfeld BI; Hathaway ES; Xin F; Tantawy MN; Haake SM; Jonasch E; Muir A; Weiss VL; Beckermann KE; Rathmell WK; Rathmell JC
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618956
[TBL] [Abstract] [Full Text] [Related]
5. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
[TBL] [Abstract] [Full Text] [Related]
6. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract] [Full Text] [Related]
7. Machine learning-based integration develops a stress response stated T cell (Tstr)-related score for predicting outcomes in clear cell renal cell carcinoma.
Yang S; Han Z; Tan Z; Wu Z; Ye J; Cai S; Feng Y; He H; Wen B; Zhu X; Ye Y; Huang H; Wang S; Zhong W; Deng Y
Int Immunopharmacol; 2024 May; 132():112017. PubMed ID: 38599101
[TBL] [Abstract] [Full Text] [Related]
8. GHITM regulates malignant phenotype and sensitivity to pd-1 blockade of renal cancer cells via Notch signalling.
Huang S; Liu J; Hu J; Hou Y; Hu M; Zhang B; Luo H; Fu S; Chen Y; Liu X; Chen Z; Wang L
J Cell Mol Med; 2024 Apr; 28(8):e18290. PubMed ID: 38588015
[TBL] [Abstract] [Full Text] [Related]
9. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract] [Full Text] [Related]
10. Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with pd-1 blockade.
Gui M; Wu C; Qi R; Zeng Y; Huang P; Cao J; Chen T; Chen K; Lin L; Han Q; He P; Fu R; Wu Q; Yuan Q; Zhang T; Xia N; Wang G; Chen Y
J Med Virol; 2024 Apr; 96(4):e29568. PubMed ID: 38549430
[TBL] [Abstract] [Full Text] [Related]
11. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
[TBL] [Abstract] [Full Text] [Related]
12. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C; Jacquel A; Pandiani C; Rastoin O; Dawaliby R; Schmitt T; Bourgoin M; Palenzuela H; Rossi AL; Ambrosetti D; Durivault J; Luciano F; Borchiellini D; Le Du J; Gonçalves LCP; Auberger P; Benhida R; Kinget L; Beuselinck B; Ronco C; Pagès G; Dufies M
J Exp Clin Cancer Res; 2024 Mar; 43(1):86. PubMed ID: 38504270
[TBL] [Abstract] [Full Text] [Related]
13. Sarcoid-like reaction and hypothyroidism induced by pd-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review.
Shrateh ON; Abugharbieh Y; Asbeh YA; Hour H; Awad I; Bannoura S
BMC Pulm Med; 2024 Mar; 24(1):123. PubMed ID: 38459507
[TBL] [Abstract] [Full Text] [Related]
14. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.
Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z
Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902
[TBL] [Abstract] [Full Text] [Related]
15. A phase II study of retifanlimab, a humanized anti-pd-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM; Schenker M; Medioni J; Mandziuk S; Majem M; Gravis G; Cornfeld M; Ranganathan S; Lou S; Csoszi T
ESMO Open; 2024 Mar; 9(3):102387. PubMed ID: 38401247
[TBL] [Abstract] [Full Text] [Related]
16. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract] [Full Text] [Related]
17. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
[TBL] [Abstract] [Full Text] [Related]
18. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Beckermann KE; Patnaik A; Winer I; Tan W; Bashir B; Kyriakopoulos CE; Sweis RF; Chamberlain M; Rini BI
Invest New Drugs; 2024 Apr; 42(2):179-184. PubMed ID: 38372949
[TBL] [Abstract] [Full Text] [Related]
19. Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma.
Tian J; Luo J; Zeng X; Ke C; Wang Y; Liu Z; Li L; Zhang Y; Hu Z; Yang C
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38355278
[TBL] [Abstract] [Full Text] [Related]
20. Single-cell combined bioinformatics analysis: construction of immune cluster and risk prognostic model in kidney renal clear cells based on CD8
Gao H; Sun H; He A; Liu H; Zhang Z; Li D; Mao W; Qian J
Eur J Med Res; 2024 Jan; 29(1):89. PubMed ID: 38291496
[TBL] [Abstract] [Full Text] [Related]
[Next]
